The role of linezolid in empirical therapy of suspected bacteremia remains unclear. The aim of this study was to evaluate the influence of empirical use of linezolid or glycopeptides in addition to other antibiotics on the 30-day mortality rates in patients with Gram-negative bacteremia. For this purpose, 1,126 patients with Gram-negative bacteremia in the Hospital Clinic of Barcelona from 2000 to 2012 were included in this study. In order to compare the mortality rates between patients who received linezolid or glycopeptides, the propensity scores on baseline variables were used to balance the treatment groups, and both propensity score matching and propensity-adjusted logistic regression were used to compare the 30-day mortality rates between the groups. The overall 30-day mortality rate was 16.0% during the study period. Sixty-eight patients received empirical treatment with linezolid, and 1,058 received glycopeptides. The propensity score matching included 64 patients in each treatment group. After matching, the mortality rates were 14.1% (9/64) in patients who received glycopeptides and 21.9% (14/64) in those who received linezolid, and a nonsignificant association between empirical linezolid treatment and mortality rate (odds ratio [OR], 1.63; 95% confidence interval [CI], 0.69 to 3.82; P ‫؍‬ 0.275, McNemar's test) was found. This association remained nonsignificant when variables that remained unbalanced after matching were included in a conditional logistic regression model. Further, the stratified propensity score analysis did not show any significant relationship between empirical linezolid treatment and the mortality rate after adjustment by propensity score quintiles or other variables potentially associated with mortality. In conclusion, the propensity score analysis showed that empirical treatment with linezolid compared with that with glycopeptides was not associated with 30-day mortality rates in patients with Gram-negative bacteremia.
T
he frequency of Gram-negative bacilli causing bloodstream infections has increased during the last 20 years, exceeding, in some communications, that of Gram-positive cocci (1) . Even in particular sources of bacteremia where Gram-positive cocci have been dominant, such as intravascular catheters, the prevalence of Gram-negative bacteria is growing (2) (3) (4) . This is of great interest since adequate selection of the initial antibiotic treatment in patients with sepsis and septic shock, which is associated with improved outcomes (5-7), depends on the suspected infection source and the presence of risk factors for specific microorganisms. However, the epidemiology of infections is complex (8) , and risk factors for different resistant pathogens are similar (9) , which might partly explain the high rate of inappropriate empirical therapy in bacteremia registries from different countries (10) (11) (12) . In any case, it is well known that patients with suspected bacteremia should initially receive a broad-spectrum antibiotic regimen against Gram-positive cocci and Gram-negative bacteria.
Vancomycin is commonly used for empirical coverage of Gram-positive cocci, especially when methicillin-resistant Staphylococcus aureus (MRSA) infection is suspected. This antibiotic, however, is associated with a high failure rate in severe nosocomial infections, including pneumonia or bacteremia due to S. aureus (13) when the MIC of vancomycin is Ն1 mg/liter (14) . Linezolid has been proposed as an effective alternative to vancomycin for the treatment of severe infections due to MRSA (15) (16) (17) , and it is being increasingly used as empirical therapy when severe MRSA infections are suspected. However, a recent clinical trial by Wilcox et al. (18) comparing empirical therapy with vancomycin versus that with linezolid in catheter-related bloodstream infections (CRBSI) showed a nonsignificant mortality rate increase in the linezolid arm in patients with Gram-negative bacillus bacteremia and a significant increase in patients with negative blood cultures. According to these data, the recently published Infectious Diseases Society of America (IDSA) guidelines for catheter-related infection management (19) strongly recommend that linezolid should not be used for empirical therapy.
However, the same article by Wilcox et al. (18) demonstrated that empirical therapy with linezolid, compared with that with vancomycin, was associated with a nonsignificant reduction in the mortality rates of episodes due to S. aureus. Further, important variables associated with mortality due to Gram-negative microorganisms, such as empirical coverage against these bacteria, were not controlled in this trial (20) . Therefore, there are reasonable doubts about the need to restrict linezolid as empirical therapy in this setting (21, 22) , and there is also a paucity of data on the safety of linezolid versus vancomycin in patients with Gram-negative bacteremia from other sources. Since it does not seem acceptable or feasible to perform a clinical trial to answer this question, analysis by suitable techniques of prospective observational studies, including a large number of patients with Gram-negative bacteremia from different sources, might provide valuable information. The aim of the present study was to evaluate the impact of empirical use of linezolid or vancomycin in addition to other antibiotics on 30-day mortality rates among patients with Gram-negative bacteremia from a prospective bacteremia registry conducted in our hospital since 1991.
MATERIALS AND METHODS
Setting. The study was conducted at the Hospital Clínic Universitari in Barcelona, Spain, a 700-bed university center that provides broad medical, surgical, and intensive care. Kidney, liver, heart, and bone marrow transplantations are performed, but the hospital lacks a burn unit.
Patients. The present study focuses on episodes of bacteremia due to Gram-negative microorganisms (specifically, Escherichia spp., Klebsiella spp., Enterobacter spp., Serratia spp., Proteus spp., Providencia spp., and Pseudomonas spp.) that were diagnosed from February 2000 through December 2012 at a single center. Only cases that had received linezolid or glycopeptides as part of empirical therapy and in addition to other antibiotics (before microbiology results were available) were included in the study.
During the study period, blood cultures were processed by the Bactec 9240 system (Becton Dickinson microbiology systems) with an incubation period of 5 days. Isolates were identified by standard techniques. Patients were consecutively enrolled in the study and were prospectively followed up. The following data were obtained for all patients: age, sex, preexisting comorbidities, prognosis of the underlying disease, current administration of Ͼ20 mg of prednisone per day (or an equivalent corticosteroid dose) for Ͼ30 days, origin of the infection (community-acquired, hospital-acquired, or health care-related), empirical treatment received, source of the bacteremia, presence of shock when blood samples were obtained for culture, need for intensive care unit (ICU) admission or mechanical ventilation during follow-up, and 30-day mortality rate.
Term definitions. Gram-negative bacteremia was considered when at least 1 blood culture was positive and clinical signs and symptoms of sepsis were present (23) . Comorbidity was defined as a disease or therapy that might predispose patients to infection, cause a functional impairment, or alter defense mechanisms. Examples include diabetes, liver cirrhosis, renal failure, alcoholism (consumption of Ͼ100 g of alcohol per day), active neoplastic disease, receipt of a bone marrow or solid organ transplant, neutropenia, severe chronic obstructive pulmonary disease, severe cardiac disease with symptomatic heart failure, HIV infection, severe dementia, and administration of immunosuppressive drugs (Ͼ20 mg of prednisone on a regular basis or antineoplastic chemotherapy). The prognosis of the underlying disease was classified, according to the modification of the criteria of McCabe and Jackson (24) , as rapidly fatal (expected death within 3 months), ultimately fatal (expected death within a period of Ͼ3 months but Ͻ5 years), and nonfatal (life expectancy of Ͼ5 years). The sources of bacteremia were divided into 3 categories: low-risk sources (related mortality rate, Ͻ10%), which included vascular catheter and endovascular sources, the ear-nose-larynx, osteoarticular sources, gynecologic sources, and several manipulation-related sources (including digestive endoscopy, arterial catheterization, and sclerosis of esophageal varices); intermediate-risk sources (associated mortality rate, 10% to 20%), which included the urinary tract, abdominal sources, and unknown sources; and high-risk sources (mortality rate, Ͼ20%), which included soft tissue sources, the lower respiratory tract, and the central nervous system (25) . Bloodstream infections were considered to be nosocomial when cultures of blood specimens obtained Ͼ48 h after hospital admission had positive results (26) , community acquired when culture samples were obtained prior to admission or during the first 48 h of hospitalization from patients without hospitalization or health care contact during the month before bacteremia, and health care-related when there was hospitalization or health care contact during the month before bacteremia (e.g., for patients receiving dialysis). The empirical treatment was considered appropriate when it was active in vitro. The isolation of the same microorganism in blood cultures after initiation of appropriate antibiotic was considered persistent bacteremia.
Statistical analysis. For the purposes of statistical analysis, the study sample was divided into two groups: patients who received empirical treatment with glycopeptides (control group) and patients who received empirical treatment with linezolid (intervention group). Continuous variables are expressed as means (standard deviations) and were compared using the Student t test. Categorical variables were expressed as a frequency (percentage) and compared using the 2 test or the Fisher exact test when necessary. Because the sample in our study was not randomized, we used the propensity score (PS) methodology to minimize the expected significant bias between the two groups (27, 28) . To do so, we constructed a nonparsimonious logistic regression model in which the dependent variable was empirical linezolid treatment started before blood culture results were available and the independent variables were those potentially associated with the decision to initiate empirical linezolid treatment. These variables only included baseline factors since the decision to start empirical treatment with linezolid or glycopeptides was made on the basis of characteristics recorded at baseline. Accordingly, the covariates introduced in the logistic regression model were age (dichotomized according to a cutoff of Ն65 years), sex, the presence of comorbidities (hematologic or solid neoplasm, diabetes, chronic kidney disease, acute kidney disease, chronic cardiac disease, chronic liver disease, chronic lung disease, HIV infection, or solid organ or bone marrow transplantation), a rapidly fatal prognosis (according to the McCabe index), previous invasive procedures, the presence of catheters (any type of vascular catheter, central vascular catheter, or urethral catheter), previous treatment with steroids, recent hospitalization (1 month), previous ICU admission, previous surgery, previous mechanical ventilation, nosocomial acquisition, a highmortality-risk source of bacteremia (i.e., soft tissue, lower respiratory tract, or central nervous system sources) (25) , the presence of fever, neutropenia, shock, disseminated intravascular coagulation, or acute respiratory distress syndrome, and embolic phenomena. The C statistic of the constructed model discriminated well between the two groups (area under the curve, 0.81; 95% confidence interval [CI], 0.77 to 0.86) (Fig. 1) , and Fig. 2 shows the PS distribution in each group. Once this model was obtained, the association between linezolid as the empirical treatment with mortality was estimated by two different methods: propensitymatched analysis and stratified PS analysis.
The propensity-matched analysis was performed by matching patients in the two groups at a 1:1 ratio, without replacement, by the nearest neighbor technique. For this purpose, we used a PS matching custom dialog for SPSS (created by F. Thoemmes, Cornell University [29, 37] ). The criterion for matching pairs used a caliper of width equal to 0.2 of the pooled standard deviation of the logit of PS (in our study, the PS pooled standard deviation was 0.074, and, therefore, the caliper was 0.0148) (30) . The standardized difference was further used to assess whether this matching technique properly balanced the baseline characteristics between the groups (31) . Absolute values of standardized difference of Ͻ10 supported the assumption of balance between the groups (32, 33) . After matching, McNemar's test was used to test the association of the mortality rate with empirical treatment with linezolid or vancomycin between matched pairs. In addition, variables considered potentially relevant risk factors for mortality that persisted unbalanced between the groups after matching by PS were included in a conditional logistic regression model to assess their potential effects on the association between the empirical treatment and mortality rate.
In addition to the propensity-matched analysis, a stratified PS analysis was performed by classifying patients into quintiles according to the probability predicted by the model. The 30-day mortality odds ratio (OR) between the groups was thus calculated using a logistic regression model individually adjusted for PS quintiles. Additionally, models were further adjusted for PS quintiles, and potentially confounding variables, which had not been included in the model to obtain the PS, were recorded after the start of the empirical treatment. These variables were the following: appropriate empirical treatment, persistent bacteremia, polymicrobial bacteremia, ICU admission, and the need for mechanical ventilation during follow-up. Thus, a different stratified PS model was built to include each of these variables, and another model was built to include all of them. A P value of Ͻ0.05 was considered statistically significant. Statistical analysis was performed using SPSS, version 20 for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
During the study period, 1,126 patients met the specified inclusion criteria. Among them, 469 patients were older than 64 years (42%), 733 patients were male (65%), and 681 bacteremias were hospital acquired (61%). The leading comorbidities were as follows: hematologic malignancies (305 patients, 27%), diabetes mellitus (220 patients, 20%), chronic kidney disease (211 patients, 19%), solid organ malignancies (193 patients, 17%), heart disease (161 patients, 14%), and solid organ or bone marrow transplantation (188 patients, 15%).
Linezolid and glycopeptides were administered as part of the empirical treatment in 68 and 1,058 patients, respectively. Table 1 shows the differences in baseline characteristics between the two groups. The linezolid group had a higher frequency of acute renal failure, urinary catheterization, mechanical ventilation, and hospital-acquired infection and a high-mortality-risk focus but a lower frequency of hematologic malignancy, bone marrow transplantation, presence of central vascular catheters, neutropenia, and appropriate empirical treatment compared to those in the glycopeptide group.
Regarding the mortality rate, 166 patients (15.7%) in the control group and 14 patients (20.6%) in the intervention group died during follow-up, but this difference was not statistically significant (OR, 1.39; 95% CI, 0.76 to 2.57; P ϭ 0.29). Other variables, such as ICU admission or mechanical ventilation during followup, also showed no statistically significant differences between the groups. Table 2 shows the microorganisms isolated during episodes of bacteremia. Propensity-matched analysis. Table 1 shows the characteristics of the patients after they were matched by PS. Overall, the groups were well balanced, and standardized differences of the variables involved in PS were Ͻ10% (31), except for the variables solid organ neoplasm, diabetes, and solid organ transplantation, which were more frequent in the intervention group, and the variable urinary catheterization, which was more frequent in the control group. Other variables potentially related to the mortality rate but not involved in the generation of the PS which were unbalanced after matching were ICU admission during follow-up, appropriate empirical antibiotic treatment, and mechanical ventilation during follow-up (the first one was more frequent in the linezolid group and the two latter were more frequent in the glycopeptide group). The mortality rates were 21.9% (14/64) in patients who received linezolid as empirical therapy and 14.1% (9/ 64) in patients who received glycopeptides. The treatment with linezolid had an OR for mortality of 1.63 (95% CI, 0.69 to 3.82). In addition, no significant association considering pairs was found (P ϭ 0.275, McNemar's test) ( Table 3 ): 43 matched pairs had a concordant outcome (42 pairs survived and 1 died) and 21 pairs had a discordant outcome (in 13 pairs, the case patient [under linezolid treatment] died and the control patient [under glycopeptide treatment] survived, while in 8 pairs, the case patient survived and the control patient died). The inclusion of variables that remained unbalanced after matching in a conditional logistic regression model to test the relationship between the empirical antibiotic treatment and the mortality rate did not change the lack of association found by McNemar's test (Table 4) .
Stratified propensity score analysis. The relationship between the empirical treatment and the 30-day mortality rate adjusted for PS quintiles and other variables obtained after the decision to start empirical treatment are shown in Table 5 . After adjustment for PS quintiles, empirical linezolid treatment was not statistically associated with the 30-day mortality rate (OR, 1.40; 95% CI, 0.74 to 2.65; P ϭ 0.30). This result did not change after adjustment for the appropriate empirical treatment, persistent bacteremia, polymicrobial bacteremia, ICU admission during follow-up, and mechanical ventilation during follow-up or after inclusion of all these variables in a fully adjusted model.
DISCUSSION
The most recent IDSA guidelines for CRBSI management (19) strongly recommend that linezolid should not be used for empirical therapy in patients suspected of having a CRBSI until the organism is identified (strength of recommendation-quality of evidence [A to I]), based on a previous study by Wilcox et al. (18) . This study was a phase III clinical trial showing that empirical treatment with linezolid was not inferior to that with vancomycin for the treatment of complicated skin and soft tissue infections and CRBSI, and in a post hoc analysis conducted in the subgroup of patients with Gram-negative bacteremia, the authors found a nonsignificant excess of deaths in the linezolid arm relative to that in the vancomycin arm. However, this was not the primary aim of the study, and critical variables associated with the mortality rates among patients with Gram-negative bacteremia, such as empirical coverage (6), had not been controlled, as was discussed by several authors afterwards (20) (21) (22) . Further randomized and controlled studies to solve this question are not reasonable, but the need to initiate broad-spectrum antibiotic coverage in patients with sepsis is a frequent clinical situation. Linezolid is one of the most commonly used drugs in this setting because of its activity against Gram-positive cocci, and there are several studies supporting its clinical efficacy (15) (16) (17) 34) . Therefore, we need additional data to confirm whether this common clinical practice is correct or not, particularly when some in vitro studies have observed an antagonistic effect between aztreonam or ceftazidime and linezolid (35) . In our study, a large series of patients with Gram-negative bacteremia were analyzed in order to test whether the inclusion of linezolid compared to glycopeptides as part of the initial empirical treatment was associated with an increased 30-day mortality rate.
Neither the crude analysis nor the adjustment by the PS techniques showed a higher mortality rate associated with the empirical use of linezolid. Interestingly, the lowest OR between the empirical treatment with linezolid and the mortality rate was observed after adjustment for adequate empirical therapy. This indicates that much of the adjustment seen in the full model takes place by this variable (Table 5 ). Indeed, it is possible that patients in our series who received linezolid were more likely to have been sicker and, therefore, had a higher probability of resistant infections and a higher risk of mortality (36) .
Some limitations to our study should be mentioned. First, PS analysis is a powerful statistical tool in observational studies to reduce imbalances between nonrandomized groups but only takes into account the measured characteristics (27) . Nonetheless, our analysis is useful because it provides valid estimates of the mortality rates in patients with Gram-negative bacteremia treated with linezolid matched with a control group treated with glycopeptides. This allows us to compare the mortality rates associated with the administration of these antimicrobials under similar conditions. Second, while the model used to obtain the PS had an acceptable calibration (area under the curve of 81%), there is still a 19% uncertainty in the model. Third, we have not analyzed adverse events after adjustment for PS between the study groups, a situation that may also influence the guidelines. Finally, we have to acknowledge that underlying diseases and comorbid conditions may also affect our main outcome measure (30-day mortality rate) in addition to acute infection.
In conclusion, in this PS analysis, the mortality rate associated with the addition of linezolid to the empirical treatment was similar to that of glycopeptides for bacteremia caused by Gram-negative bacteria. Based on these results, linezolid is an acceptable choice for the empirical treatment of bacteremia regardless of the possibility of participation of Gram-negative bacteria. 
